Literature DB >> 26680846

Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 Hospitals.

Jong Myon Bae, Young Joo Won, Kyu Won Jung, Jae Gahb Park.   

Abstract

PURPOSE: The Korea Central Cancer Registry (KCCR) program completed a nationwide hospital-based cancer registry to provide basic statistical data on cancer incidence.
MATERIALS AND METHODS: In 2000, 131 hospitals participated in the KCCR program. All cancer registry data, which were submitted by the participating hospitals during the year, were reviewed and analyzed by the committee members.
RESULTS: Of the 94,474 cases that were registered, 7,735 (8.2%) duplication cases were excluded. Of the remaining 86,739 cases, 2,893 cases (3.3%) of carcinoma in situ (morphology code/2) were excluded, leaving a final total of 83,846 cases for analysis, 48,005 (57.3%) male and 35,841 (42.7%) female. The leading age group was 60-64years (15.1%). The six leading primary cancer sites in the order of their relative frequency were the stomach (20.8%), lung (12.2%), liver (12.2%), colorectum (10.3%), breast (6.5%), and uterine cervix (4.5%). In males, the three leading primary cancer sites were the stomach (24.5%), liver (16.3%), and lung (16.3%). In females, the stomach (15.8%), breast (15.1%), and uterine cervix (10.6%). Among the 1,126 cases of childhood malignancies, leukemia (32.7%) was the most common cancer type.
CONCLUSION: We report our analysis of the KCCR data from 131 nationwide hospitals during 2000.

Entities:  

Keywords:  Annual reports; Neoplasms; Registries

Year:  2002        PMID: 26680846     DOI: 10.4143/crt.2002.34.2.77

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  18 in total

1.  Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy.

Authors:  Se Hoon Park; Moon Sook Cho; Young Saing Kim; Junshik Hong; Eunmi Nam; Jinny Park; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee; Woon Kee Lee
Journal:  Qual Life Res       Date:  2008-01-26       Impact factor: 4.147

2.  The synergism between Belotecan and cisplatin in gastric cancer.

Authors:  Joo Young Jung; Sang Hyun Song; Tae-Young Kim; Jung Hyun Park; Hyun-Soon Jong; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Noe Kyoung Kim
Journal:  Cancer Res Treat       Date:  2006-09-30       Impact factor: 4.679

3.  A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer.

Authors:  Se Hoon Park; Soo Yeon Jeon; Kwang Il Ko; Eunmi Nam; Soo-Mee Bang; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee; Woon Ki Lee; Min Chung
Journal:  Cancer Res Treat       Date:  2006-06-30       Impact factor: 4.679

4.  Malignancies in Korean patients with inflammatory myopathy.

Authors:  Sang-Won Lee; Sang Youn Jung; Min-Chan Park; Yong-Beom Park; Soo-Kon Lee
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

5.  Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.

Authors:  Hyuk-Chan Kwon; Sung Yong Oh; Suee Lee; Sung-Hyun Kim; Hyo-Jin Kim
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

6.  Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis.

Authors:  Won-Suk Lee; Min Jung Kim; Seong Hyeon Yun; Ho-Kyung Chun; Woo Yong Lee; Sung-Joo Kim; Seong-Ho Choi; Jin-Seok Heo; Jae Won Joh; Yong Il Kim
Journal:  Langenbecks Arch Surg       Date:  2007-10-02       Impact factor: 3.445

7.  A phase II study of paclitaxel and cisplatin as salvage therapy for patients with advanced or metastatic gastric cancer.

Authors:  Bong-Gun Seo; Sung Yong Oh; Dong Mee Lee; Hyun Seung Yoo; Suee Lee; Seong-Geun Kim; Sung-Hyun Kim; Hyuk-Chan Kwon; Hyo-Jin Kim
Journal:  Cancer Res Treat       Date:  2007-03-31       Impact factor: 4.679

8.  Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa.

Authors:  Hae Yeon Kang; Nayoung Kim; Young Soo Park; Jin-Hyeok Hwang; Jin-Wook Kim; Sook Hyang Jeong; Dong Ho Lee; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

9.  Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.

Authors:  Se Hoon Park; Yuna Lee; Sang Hoon Han; So Young Kwon; Oh Sang Kwon; Sun Suk Kim; Ju Hyun Kim; Yeon Ho Park; Jeong Nam Lee; Soo-Mee Bang; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  BMC Cancer       Date:  2006-01-05       Impact factor: 4.430

10.  A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers.

Authors:  Jeeyun Lee; Sung Kim; Phillip Kim; Xinjun Liu; Tani Lee; Kyoung-Mee Kim; In-Gu Do; Joon Oh Park; Se Hoon Park; Jiryeon Jang; Nicholas Hoe; Gulia Harvie; Anne Kuller; Anjali Jain; Gary Meyer; Glen Leesman; Young Suk Park; Min Gew Choi; Tae Sung Sohn; Jae Moon Bae; Ho Yeong Lim; Sharat Singh; Won Ki Kang
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.